Diploma (DPLM) Price Target Increased to GBX 1,600 by Analysts at Peel Hunt

Diploma (LON:DPLM) had its target price hoisted by Peel Hunt from GBX 1,400 ($18.29) to GBX 1,600 ($20.91) in a research report issued on Monday, ThisIsMoney.Co.Uk reports. The firm presently has an “add” rating on the stock. Peel Hunt’s price target points to a potential upside of 4.30% from the company’s current price.

A number of other research firms also recently weighed in on DPLM. Numis Securities reissued a “hold” rating and set a GBX 1,420 ($18.55) price target on shares of Diploma in a research report on Wednesday, March 27th. Berenberg Bank reduced their price objective on Diploma from GBX 1,435 ($18.75) to GBX 1,350 ($17.64) and set a “hold” rating on the stock in a research note on Tuesday, January 29th. Finally, HSBC initiated coverage on Diploma in a research note on Tuesday, February 12th. They set a “hold” rating and a GBX 1,325 ($17.31) price objective on the stock. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,412.86 ($18.46).

DPLM stock opened at GBX 1,534 ($20.04) on Monday. Diploma has a twelve month low of GBX 1,144 ($14.95) and a twelve month high of GBX 1,654 ($21.61). The company has a market cap of $1.74 billion and a PE ratio of 32.23.

In other news, insider Johnny Thomson acquired 22,000 shares of Diploma stock in a transaction that occurred on Monday, February 25th. The shares were purchased at an average cost of GBX 1,349 ($17.63) per share, for a total transaction of £296,780 ($387,795.64).

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in North America, Europe, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies consumables and instruments for the diagnostic testing of blood, tissue, and other samples in hospital pathology and life sciences laboratories; electrosurgery and minimally invasive surgery equipment and consumables for use in hospital operating rooms; and surgical medical devices, and related consumables and services to GI endoscopy suites in hospitals and private clinics.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Analyst Recommendations for Diploma (LON:DPLM)

Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.